お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
979967

KRAS阻害薬の世界市場 - 機会・臨床試験の見通し

Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025

出版日: | 発行: KuicK Research | ページ情報: 英文 125 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

KRAS阻害薬の世界市場 - 機会・臨床試験の見通し
出版日: 2021年01月05日
発行: KuicK Research
ページ情報: 英文 125 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

KRAS阻害薬は、市場に関連する素晴らしい研究開発パイプラインにより、がん治療薬市場のトップの新興部門の1つであると言えます。

当レポートでは、世界のKRAS阻害薬市場について調査分析し、市場機会、市場シェア、臨床試験中の薬剤、市場動向、市場力学、将来の機会見通しについて、体系的な情報を提供しています。

目次

第1章 KRAS阻害薬のイントロダクション

第2章 がんにおけるKRAS阻害薬の役割

第3章 KRAS阻害薬:作用機序

第4章 肺がんを標的とするKRAS阻害薬

  • 肺がんに対するKRAS阻害薬の影響
  • 進行中の研究開発

第5章 膵臓がんにおけるKRAS阻害薬

  • 膵臓がんにおけるKRAS阻害薬の役割
  • KRAS阻害薬を標的とする膵臓がんにおける最近の進歩

第6章 大腸がんにおけるKRAS阻害薬

  • 大腸がんに対するKRAS阻害薬の可能性
  • 進行中の研究開発

第7章 その他のがんに対するKRAS阻害薬

  • 血液がん治療薬としてのKRAS阻害薬の可能性
  • 前立腺がんにおけるKRAS阻害薬
  • 胃がんにおけるKRAS阻害薬
  • 子宮内膜がんにおけるKRAS阻害薬
  • 脳腫瘍におけるKRAS阻害薬の役割

第8章 世界のKRASタンパク質阻害薬の臨床試験の指標

  • フェーズ別
  • 国別
  • 企業別
  • 適応症別
  • 患者セグメント別

第9章 世界のKRASタンパク質阻害薬の臨床パイプライン:企業別、適応症別、フェーズ別

  • 研究
  • 前臨床
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズIII

第10章 世界のKRAS阻害薬市場分析:現在のシナリオ

第11章 世界のKRAS阻害薬市場の動向

第12章 世界のKRAS阻害薬市場力学

  • KRAS阻害薬市場の促進要因
  • KRAS阻害薬市場の課題

第13章 世界のKRAS阻害薬市場の将来の機会見通し

第14章 競合情勢

  • Amgen
  • Mirati Therapeutics
  • Revolution Medicines
  • Boehringer Ingelheim
  • Merck
  • Moderna
  • Silenseed
  • Johnson & Johnson
  • Eli Lilly
  • Oblique Therapeutics
  • Cotinga Pharmaceuticals
  • Codiak Biosciences
  • Gilead
図表

List of Figures

  • Figure 1-1: RAS Mutation - Frequency of KRAS Mutation v/s HRAS & NRAS Mutations
  • Figure 1-2: Historical Development of KRAS Inhibitors
  • Figure 2-1: KRAS Mutational Frequency by Organs (%)
  • Figure 2-2: Roles of KRAS Inhibitors in Cancer Treatment
  • Figure 3-1: General Mechanism of KRAS Inhibitors against Cancer
  • Figure 3-2: Targeting Approaches of KRAS Inhibitors
  • Figure 3-3: Direct Targeting of Mutant KRAS
  • Figure 3-4: Targets for Modifying the KRAS Membrane Association
  • Figure 4-1: Global - Newly Diagnosed Cases & Deaths related to Lung Cancer (Million), 2020
  • Figure 4-2: Global - Lung Cancer Incidence by Type (%), 2020
  • Figure 4-3: Impact of KRAS Inhibitor on Lung Cancer
  • Figure 4-4: Investigational KRAS Inhibitors for Lung Cancer
  • Figure 4-5: Codebreak 200 Trial - Study Initiation & Expected Completion Year
  • Figure 4-6: Codebreak 105 Trial - Study Initiation & Expected Completion Year
  • Figure 4-7: Codebreak 101 Trial - Study Initiation & Expected Completion Year
  • Figure 4-8: Krystal 7 trial - Study Initiation & Expected Completion Year
  • Figure 4-9: Krystal 1 trial - Study Initiation & Expected Completion Year
  • Figure 4-10: Krystal 2 trial - Study Initiation & Expected Completion Year
  • Figure 4-11: BI-1701963 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 4-12: mRNA-5671 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 4-13: Mechanism of BI-2852 against Lung Cancer
  • Figure 5-1: Global - Newly Diagnosed Cases & Deaths related to Pancreatic Cancer, 2020
  • Figure 5-2: Ideal Targets of Inhibiting KRAS Mutation of Pancreatic Cancer
  • Figure 5-3: Role of KRAS Inhibitors in Pancreatic Cancer
  • Figure 5-4: Investigational KRAS Inhibitors for Pancreatic Cancer
  • Figure 5-5: siG12D LODER Phase II Trial - Study Initiation & Expected Completion Year
  • Figure 5-6: iExosomes Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 5-7: KRAS mTCR PBL Phase I/II Trial - Study Initiation & Expected Completion Year
  • Figure 6-1: Global - Newly Diagnosed Cases & Deaths related to Colon Cancer (Million), 2020
  • Figure 6 -: Global - Newly Diagnosed Cases & Deaths related to Rectum Cancer (Million), 2020
  • Figure 6-3: Ideal Targets for Inhibiting KRAS Mutation of Pancreatic Cancer
  • Figure 6-4: Investigational KRAS Inhibitors for Colorectal Cancer
  • Figure 7-1: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 7-2: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 7-3: Frequency of KRAS Mutation in Hematological Cancer (%)
  • Figure 7-4: Global - Newly Diagnosed Cases & Deaths related to Prostate Cancer (Million), 2020
  • Figure 7-5: Global - Number of Newly Diagnosed Gastric Cancer Cases & Deaths, 2020
  • Figure 7-6: Global - Number of Newly Diagnosed Cases of Endometrial Cancer by Type, 2020
  • Figure 7-7: Global - Number of Deaths of Endometrium Cancer by Type, 2020
  • Figure 7-8: Global - Newly Diagnosed Cases & Deaths related to Brain Cancer, 2020
  • Figure 8-1: Global - KRAS Protein inhibitors Clinical Trials by Phase, 2020 -2025
  • Figure 8-2: Global - KRAS Protein inhibitors Clinical Trials by Country, 2020 -2025
  • Figure 8-3: Global - KRAS Protein inhibitors Clinical Trials by Company, 2020 -2025
  • Figure 8-4: Global - KRAS Protein inhibitors Clinical Trials by Indication, 2020 -2025
  • Figure 8-5: Global - KRAS Protein inhibitors Clinical Trials by Patient Segment, 2020 -2025
  • Figure 12-1: Drivers for KRAS Inhibitor Market
  • Figure 12-2: Challenges for KRAS Inhibitor Market
  • Figure 12-3: Global - Estimated Monthly Treatment Cost of AMG 150 v/s Other Cell Signal Targeting Therapeutics
  • Figure 13-1:- US - Expected Monthly & Full Treatment Cost of KRAS Inhibitors (US$), November'2020
  • Figure 13-2: Global - Estimated KRAS Inhibitors Market (US$ Million), 2023 - 2025
  • Figure 13-3: US v/s Non US Markets - KRAS Inhibitors Market Share (%), 2023 - 2025
目次

"Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025" Report Highlights:

  • KRAS Inhibitors Market Opportunity: > USD 1 Billion by 2025
  • Initially US To Dominate KRAS Inhibitors Market: >90% Market Share
  • Number of KRAS Inhibitors In Trials: > 20 Drugs
  • Highest Phase of Clinical Development: Phase-III Study
  • Solid Tumors Targeted Drugs Dominating The Clinical Trials
  • Global KRAS Inhibitors Market Trends & Dynamics
  • Global KRAS Inhibitors Market Future Opportunity Outlook

The accelerating pace of the cancer cases at global level has led to the arrival of a unique and application-based therapy market, known as KRAS inhibitors. In the past few years, the therapy has been able to show favorable response involving the cell cycle, which is the ultimate target of the cancer cells for continue its proliferation and division in the patients. A cluster of innovative drugs that target KRAS protein has been developed by the researchers and bunch of novel product candidate targeting KRAS protein is currently active in the clinical trials. It can be stated for KRAS inhibitors that it is among the top emerging sectors of the cancer therapeutics market which is due to the splendid research and development pipeline associated with the market. The entire market associated with KRAS inhibitors, in a very short period of time has been able to shift the entire cancer landscape, thus resulting in the standard care of cancer treatment with appropriate opportunities to the patients and the investors.

The drugs developed under the market, inhibits KRAS protein and further the important signaling pathways, ultimately leading to the cell cycle arrest and killing of the cancer cells. Such switching on and off of the cell cycle with the help of hundreds of KRAS inhibitors developed by the researchers is estimated to improve the overall paradigm for efficient targeting, minimal side-effect development, increased effectiveness and efficiency against different types of tumor antigens. The overall increase in the spending for research-based formulas for KRAS inhibitors is also estimated to develop a market that is worth trillions of dollars and decrease the burden that is getting reflected in the cancer therapeutics market with respect to efficient targeting of the cancer cells.

Despite having numerous challenges which were set by the already driven cancer therapies in the market such as chemotherapy or radiation therapy, the novel KRAS inhibitor market has made its impact on the overall running paradigm of cancer therapeutics at global level. The pharmaceutical research sector affiliated with KRAS inhibitor market has weathered down the complex challenges of developing drug candidates with 100% efficacy.

Now-a-days, the KRAS inhibitor market at global level is getting adjoined with novel techniques and technologies that are apparently leading to reinventing the entire cancer market and research-based sector. No doubt, the entire market has led to an opening of novel frontiers that could unravel the complex mechanism of cancer cells and how it could get regulated by controlling the proteins responsible for cell cycle. In addition to this, some of the parameters that are leading to the exponential growth of the market in the past few years include: healthcare benefits associated with the drug candidates and increased awareness about the side-effects of old and traditional cancer therapies such as chemotherapy.

As per the "Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025" report findings, it can be estimated that the market is completely getting catalyzed by the increased applications of healthcare benefits and variety of disruptive technologies and drug candidates that are available in the market for different types of tumor antigens. In the novel cancer therapeutics market, partly driven by KRAS inhibitor is believed to be overcoming all the challenges that were difficult to crack before the arrival of the KRAS inhibitor therapy.

Table of Contents

1. Introduction to KRAS Inhibitors

  • 1.1 Overview
  • 1.2 Evolution of KRAS Inhibitors

2. Role of KRAS Inhibitors in Cancer

3. KRAS Inhibitors - Mode of Action

4. KRAS Inhibitors For Targeting Lung Cancer

  • 4.1 Impact of KRAS Inhibitors on Lung Cancer
  • 4.2 Ongoing Research & Development
    • 4.2.1 AMG 510 (Sotorasib)
    • 4.2.2 MRTX849 (Adagrasib)
    • 4.2.3 Other Investigational KRAS Inhibitors for Lung Cancer

5. KRAS Inhibitors in Pancreatic Cancer

  • 5.1 Role of KRAS Inhibitors in Pancreatic Cancer
  • 5.2 Recent Advancement in Pancreatic Cancer Targeting KRAS Inhibitors

6. KRAS Inhibitors for Colorectal Cancer

  • 6.1 Potential of KRAS Inhibitors Against Colorectal Cancer
  • 6.2 Ongoing Research & Development

7. KRAS inhibitors For Other Cancers

  • 7.1 Potential of KRAS Inhibitors as Hematological Cancer Therapeutics
  • 7.2 KRAS inhibitors in Prostate Cancer
  • 7.3 KRAS Inhibitors for Gastric Cancer
  • 7.4 KRAS Inhibition in Endometrium Cancer
  • 7.5 Role of KRAS Inhibitors in Brain Cancer

8. Global KRAS Protein inhibitors Clinical Trials Indicators

  • 8.1 By Phase
  • 8.2 By Country
  • 8.3 By Company
  • 8.4 By Indication
  • 8.5 By Patient Segment

9. Global KRAS Protein Inhibitors Clinical Pipeline By Company, Indication & Phase

  • 9.1 Research
  • 9.2 Preclinical
  • 9.3 Phase-I
  • 9.4 Phase-I/II
  • 9.5 Phase-II
  • 9.6 Phase-III

10. Global KRAS Inhibitors Market Analysis: Current Scenario

11. Global KRAS Inhibitors Market Trends

  • 11.1 Revolution Medicines' KRAS-G12(ON) Inhibitor Shows Prominent Anti-Tumor Activity
  • 11.2 Boehringer Ingelheim & Mirati Therapeutics Collaborated to Study Combinational KRAS Inhibitor Therapy
  • 11.3 Merck Signed a Licensing Deal with Taiho & Astex for Developing KRAS Targeting Therapies
  • 11.4 Strata Collaborated with Mirati Therapeutics for Conducting Trial of MRTX849
  • 11.5 Revolution Medicine Collaborated with Amgen to Evaluate SHP2 & KRAS Inhibitors Combinational Therapy
  • 11.6 Oncogenuity - New Player in KRAS Inhibitor Development
  • 11.7 Miratis & Novartis Collaborated to Assess KRAS Inhibitor Based Combinational Therapy

12. Global KRAS Inhibitors Market Dynamics

  • 12.1 Driving Factors for KRAS Inhibitor Market
  • 12.2 Challenges for KRAS Inhibitors Market

13. Global KRAS Inhibitors Market Future Opportunity Outlook

14. Competitive Landscape

  • 14.1 Amgen
  • 14.2 Mirati Therapeutics
  • 14.3 Revolution Medicines
  • 14.4 Boehringer Ingelheim
  • 14.5 Merck
  • 14.6 Moderna
  • 14.7 Silenseed
  • 14.8 Johnson & Johnson
  • 14.9 Eli Lilly
  • 14.10 Oblique Therapeutics
  • 14.11 Cotinga Pharmaceuticals
  • 14.12 Codiak Biosciences
  • 14.13 Gilead
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.